Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.

Cosmos Health Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DIGITAL SUBSCRIPTION PLATFORM BRINGS TOGETHER THE COMPANY'S PROPRIETARY CONSUMER HEALTH PRODUCTS ACROSS CONSUMER (B2C) AND CORPORATE (B2B) CHANNELS CUSTOMERS CAN BEGIN THROUGH ONE OF THREE PATHS: A FREE NUTRITIONIST CONSULTATION, AN AI-POWERED ASSISTANT, OR BUILDING THEIR OWN PACKAGE CORPORATE OFFERING SUPPORTS EMPLOYEE WELLNESS PROGRAMS AND CORPORATE GIFTING THROUGH MULTI-RECIPIENT MANAGEMENT, TIERED VOLUME PRICING, CENTRALIZED BILLING, AND DEDICATED ACCOUNT MANAGEMENT FUTURE PLATFORM ENHANCEMENTS ARE EXPECTED TO INCLUDE AI-DRIVEN PERSONALIZATION AND THE POTENTIAL INTEGRATION OF AT-HOME TESTING AND DIAGNOSTIC KITS PLATFORM BUILDS ON THE U.S. SUBSCRIPTION LAUNCH OF NOOR COLLAGEN, WHICH HAS DELIVERED AN EARLY REPEAT PURCHASE RATE ABOVE 60% CHICAGO, JULY 27, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT IS ACTIVELY DEVELOPING A FLEXIBLE, TECHNOLOGY-DRIVEN SUBSCRIPTION PLATFORM FOR ITS CONSUMER HEALTH PRODUCTS, REPRESENTING A SIGNIFICANT STEP IN THE COMPANY'S BROADER TECHNOLOGY-DRIVEN TRANSFORMATION. DESIGNED AROUND CUSTOMER CHOICE, THE PLATFORM WILL ALLOW CUSTOMERS TO BEGIN WITH A FREE CONSULTATION WITH A NUTRITIONIST, ENGAGE WITH AN AI-POWERED ASSISTANT, OR SELECT PRODUCTS AND BUILD THEIR OWN PACKAGE.

COSMOS HEALTH ADVANCES ITS TECHNOLOGY-DRIVEN TRANSFORMATION WITH AN AI-ENABLED SUBSCRIPTION PLATFORM ACROSS B2C AND B2B CHANNELS

COSMOS HEALTH EXPANDS ITS SKY PREMIUM LIFE PARTNERSHIP WITH PHARMA CELL IN ALBANIA, WITH AVERAGE MONTHLY ORDERS ALREADY EXCEEDING 4,500 UNITS, AND PROJECTED TO EXCEED 54,000 ANNUALLY PRODUCTS ARE DISTRIBUTED ACROSS ALBANIA AND RECOMMENDED BY DOCTORS AND HEALTHCARE PROFESSIONALS, SUPPORTING BROAD CONSUMER ACCESS EXPANSION BUILDS ON THE PARTNERSHIP LAUNCHED IN APRIL 2025 AND REFLECTS SKY PREMIUM LIFE'S CONTINUED GLOBAL GROWTH CHICAGO, JULY 20, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED AN EXPANSION OF ITS PARTNERSHIP WITH PHARMA CELL FOR THE DISTRIBUTION OF ITS SKY PREMIUM LIFE BRAND IN ALBANIA. BUILDING ON THE PARTNERSHIP THE COMPANIES LAUNCHED IN APRIL 2025, AND REFLECTING THE STRONG RECEPTION OF SKY PREMIUM LIFE IN THE ALBANIAN MARKET, THE COMPANY ANTICIPATES THAT ORDERS UNDER THE EXPANDED RELATIONSHIP WILL EXCEED 54,000 UNITS ON AN ANNUALIZED BASIS, WITH AVERAGE MONTHLY ORDERS ALREADY EXCEEDING 4,500 UNITS.

COSMOS HEALTH EXPANDS PHARMA CELL PARTNERSHIP IN ALBANIA WITH ANNUALIZED ORDERS PROJECTED TO EXCEED 54,000 UNITS

CHICAGO, JULY 17, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 274,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.2554 PER SHARE. THE COMPANY HAS NOW REPURCHASED A TOTAL OF 5,112,000 SHARES FOR APPROXIMATELY $1.11 MILLION UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH SHARE BUYBACK EXPANDS TO 5.11 MILLION SHARES; CONTINUES OPEN MARKET REPURCHASES

CHICAGO, JULY 16, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 250,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.2782 PER SHARE. THE COMPANY HAS NOW REPURCHASED A TOTAL OF 4,838,000 SHARES FOR APPROXIMATELY $1.04 MILLION UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH SHARE BUYBACK SURPASSES $1 MILLION, REACHING 4.84 MILLION SHARES; CONTINUES OPEN MARKET REPURCHASES

CHICAGO, JULY 15, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 100,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.2928 PER SHARE. THE COMPANY HAS NOW REPURCHASED A TOTAL OF 4,588,000 SHARES FOR APPROXIMATELY $970,000 UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH SHARE BUYBACK SURPASSES 4.5 MILLION SHARES; CONTINUES OPEN MARKET REPURCHASES

CHICAGO, JULY 14, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 133,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.298 PER SHARE. THE COMPANY HAS NOW REPURCHASED A TOTAL OF APPROXIMATELY 4,488,000 SHARES FOR APPROXIMATELY $941,000 UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH SHARE BUYBACK EXPANDS TO 4.49 MILLION SHARES; CONTINUES OPEN MARKET REPURCHASES

CHICAGO, JULY 13, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 215,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.325 PER SHARE. THE COMPANY HAS NOW REPURCHASED A TOTAL OF 4,355,000 SHARES FOR APPROXIMATELY $901,000 UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH SHARE BUYBACK REACHES 4.36 MILLION SHARES; CONTINUES OPEN MARKET REPURCHASES

COSMOS HEALTH WILL SUPPLY DIABIT-IS X (SITAGLIPTIN), WHILE LIBYTEC HANDLES DISTRIBUTION AND PROMOTION IN GREECE FIVE-YEAR AGREEMENT EXPECTED TO CONTRIBUTE TO REVENUE AND CASH-FLOW VISIBILITY AS A PRESCRIPTION MEDICINE, DIABIT-IS X IS EXPECTED TO BE ACCESSIBLE TO PATIENTS THROUGH GREECE'S NATIONAL HEALTH INSURANCE SYSTEM, BROADENING ITS POTENTIAL REACH DIABIT-IS X IS A GENERIC ALTERNATIVE TO MERCK'S JANUVIA, WHICH WITH JANUMET GENERATED APPROXIMATELY $4.5 BILLION IN COMBINED GLOBAL SALES IN 2022 POSITIONS COSMOS HEALTH IN THE LARGE AND ESTABLISHED EUROPEAN SITAGLIPTIN MARKET CHICAGO, JULY 13, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT FOR THE COMMERCIALIZATION OF ITS TYPE-2 DIABETES MEDICATION DIABIT-IS X (SITAGLIPTIN PHOSPHATE) IN THE GREEK MARKET, THROUGH A DISTRIBUTION AND PROMOTION PARTNERSHIP WITH LIBYTEC PHARMACEUTICAL S.A. ("LIBYTEC").

COSMOS HEALTH ACCELERATES PRESCRIPTION MEDICINE STRATEGY WITH LIBYTEC PARTNERSHIP TO COMMERCIALIZE DIABIT-IS X IN GREECE

SUBSCRIPTION MODEL ALREADY LAUNCHED WITH NOOR COLLAGEN IN THE UNITED STATES EARLY DATA SHOWS A REPEAT PURCHASE RATE ABOVE 60% AT HIGH MARGINS IN EXCESS OF 50% MODEL IS DESIGNED TO DRIVE STRONGER LOYALTY, GREATER LIFETIME VALUE, AND MORE PREDICTABLE CASH-FLOW VISIBILITY COMPANY PLANS TO EXTEND THE SUBSCRIPTION MODEL TO ADDITIONAL COSMOS HEALTH PRODUCTS GLOBALLY, WITH FURTHER INITIATIVES ALREADY UNDERWAY CHICAGO, JULY 10, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS LAUNCHED A SUBSCRIPTION-BASED PURCHASING MODEL FOR ITS PROPRIETARY CONSUMER HEALTH BRANDS. THE MODEL IS CURRENTLY LIVE WITH NOOR COLLAGEN IN THE UNITED STATES, WITH ENCOURAGING EARLY RESULTS THAT INCLUDE A REPEAT PURCHASE RATE ABOVE 60% AND MARGINS IN EXCESS OF 50%.

COSMOS HEALTH LAUNCHES SUBSCRIPTION MODEL

CHICAGO, JULY 09, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 80,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.2503 PER SHARE. THE COMPANY HAS NOW REPURCHASED A TOTAL OF 4,140,000 SHARES FOR APPROXIMATELY $831,000 UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH EXPANDS SHARE BUYBACK TO 4.14 MILLION SHARES; CONTINUES OPEN MARKET REPURCHASES

CHICAGO, JULY 08, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. (COSMOS HEALTH OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 190,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.2805 PER SHARE. THE COMPANY HAS NOW REPURCHASED A TOTAL OF 4,060,000 SHARES FOR APPROXIMATELY $811,000 UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH SHARE BUYBACK SURPASSES 4 MILLION SHARES; CONTINUES OPEN MARKET REPURCHASES

CHICAGO, JULY 07, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 230,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.2539 PER SHARE. THE COMPANY HAS NOW REPURCHASED A TOTAL OF 3,870,000 SHARES FOR APPROXIMATELY $758,000 UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH SHARE BUYBACK EXPANDS TO 3.87 MILLION SHARES; CONTINUES OPEN MARKET REPURCHASES

RECORD Q2 2026 REVENUE OF APPROXIMATELY $19.4 MILLION, UP APPROXIMATELY 31.5% YEAR-OVER-YEAR FROM $14.75 MILLION IN Q2 2025 RECORD FIRST-HALF 2026 REVENUE OF APPROXIMATELY $37.3 MILLION, UP APPROXIMATELY 31% FROM $28.46 MILLION IN H1 2025 3,640,000 SHARES REPURCHASED AS OF JULY 6, 2026 FOR APPROXIMATELY $700,000 UNDER THE COMPANY'S $5 MILLION BUYBACK PROGRAM, WITH OPEN MARKET PURCHASES ONGOING CHICAGO, JULY 07, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY PROVIDED A BUSINESS UPDATE ON ITS SECOND QUARTER AND FIRST-HALF REVENUE PERFORMANCE AND SHARE REPURCHASE ACTIVITY. RECORD Q2 AND H1 2026 REVENUE: BASED ON PRELIMINARY RESULTS, THE COMPANY EXPECTS TO REPORT SECOND-QUARTER 2026 REVENUE OF APPROXIMATELY $19.4 MILLION, UP APPROXIMATELY 31.5% FROM $14.75 MILLION IN Q2 2025, AND FIRST-HALF REVENUE OF APPROXIMATELY $37.3 MILLION, UP APPROXIMATELY 31% FROM $28.46 MILLION IN H1 2025  BOTH THE HIGHEST IN THE COMPANY'S HISTORY.

COSMOS HEALTH REPORTS PRELIMINARY RECORD Q2 AND H1 2026 REVENUE, UP OVER 30% YEAR-OVER-YEAR; CONTINUES OPEN MARKET SHARE REPURCHASES

CHICAGO, JULY 06, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 220,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.2229 PER SHARE, CONTINUING THE BUYBACK ACTIVITY CARRIED OUT UNDER ITS ONGOING REPURCHASE PROGRAM. THE COMPANY HAS NOW REPURCHASED A TOTAL OF 3,640,000 SHARES FOR APPROXIMATELY $700,000 UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH SHARE BUYBACK INCREASES TO 3.64 MILLION SHARES; CONTINUES OPEN MARKET PURCHASES

CHICAGO, JULY 02, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED AN ADDITIONAL 770,000 SHARES OF ITS COMMON STOCK IN THE OPEN MARKET AT AN AVERAGE PRICE OF APPROXIMATELY $0.1956 PER SHARE, EXTENDING THE BUYBACK ACTIVITY IT BEGAN THIS WEEK. THE COMPANY HAS NOW REPURCHASED A TOTAL OF 3,420,000 SHARES FOR APPROXIMATELY $650,000 UNDER ITS PREVIOUSLY ANNOUNCED SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION.

COSMOS HEALTH EXPANDS BUYBACK TO 3.42 MILLION SHARES WITH ADDITIONAL 770,000-SHARE REPURCHASE; CONTINUES OPEN MARKET PURCHASES

CHICAGO, JULY 01, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS REPURCHASED 2,650,000 SHARES OF ITS COMMON STOCK FOR A TOTAL OF $500,000 IN THE OPEN MARKET, AT AN AVERAGE PRICE OF APPROXIMATELY $0.1887 PER SHARE. THE REPURCHASES WERE MADE PURSUANT TO THE SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION ANNOUNCED ON JUNE 30, 2026, UNDER WHICH THE COMPANY MAY REPURCHASE SHARES FROM TIME TO TIME IN THE OPEN MARKET, THROUGH PRIVATELY NEGOTIATED TRANSACTIONS, OR THROUGH OTHER PERMITTED MEANS IN ACCORDANCE WITH SEC RULES 10B5-1 AND 10B-18 AND OTHER APPLICABLE RESTRICTIONS.

COSMOS HEALTH COMPLETES INITIAL REPURCHASE OF 2.65 MILLION SHARES FOR $500,000; CONTINUES OPEN MARKET BUYBACKS AT CURRENT PACE

CHICAGO, JUNE 30, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED A SHARE REPURCHASE PROGRAM OF UP TO $5 MILLION OF THE COMPANY'S COMMON STOCK. COSMOS HEALTH MAY REPURCHASE SHARES FROM TIME TO TIME IN THE OPEN MARKET, THROUGH PRIVATELY NEGOTIATED TRANSACTIONS, OR THROUGH OTHER PERMITTED MEANS IN ACCORDANCE WITH SEC RULES 10B5-1 AND 10B-18 AND OTHER APPLICABLE RESTRICTIONS.

COSMOS HEALTH AUTHORIZES UP TO $5 MILLION SHARE REPURCHASE PROGRAM

COSMOS HEALTH SIGNS DISTRIBUTION AGREEMENT WITH IMC, OWNER OF QATAR'S LARGEST PHARMACY CHAIN. SECURES PURCHASE ORDER OF 31,000 SKY PREMIUM LIFE UNITS.

COSMOS HEALTH SIGNS DISTRIBUTION AGREEMENT WITH IMC, OWNER OF QATAR'S LARGEST PHARMACY CHAIN; SECURES INITIAL PURCHASE ORDER OF 31,000 SKY PREMIUM LIFE UNITS

BUILDING ON ITS RECENT ACQUISITION OF THE CCX0722 INTELLECTUAL PROPERTY, COSMOS HEALTH OWNS THE TECHNOLOGY OUTRIGHT AND IS NOW PURSUING PATENT PROTECTION ACROSS FOUR MAJOR HEALTHCARE MARKETS WITHIN THE $190+ BILLION GLOBAL WEIGHT MANAGEMENT CATEGORY ADVANCES INTERNATIONAL PATENT APPLICATION WO2025108566A1, TITLED "HYDROGEL FOR BODY WEIGHT MANAGEMENT," INTO THE U.S., EUROPE, AUSTRALIA, AND CANADA  FOUR OF THE WORLD'S LARGEST HEALTHCARE MARKETS BUILDS ON CANA LABORATORIES' ACQUISITION OF THE PATENT APPLICATION FROM CLOUDPHARM, BRINGING FULL OWNERSHIP OF THE UNDERLYING INTELLECTUAL PROPERTY INTO THE COSMOS HEALTH PORTFOLIO, WITH NO LICENSING FEES, ROYALTY-SHARING, OR THIRD-PARTY IP DEPENDENCY THREE-PLUS YEARS OF DISCIPLINED R&D EXECUTION  FROM CONCEPT IN 2022 THROUGH PILOT PRODUCTION, SCALE-UP, AND FINAL-STAGE DEVELOPMENT POSITIONED WITHIN THE RAPIDLY GROWING GLOBAL WEIGHT MANAGEMENT MARKET, ESTIMATED AT $190.6 BILLION IN 2025 AND PROJECTED TO REACH $562.2 BILLION BY 2033 AT A 14.2% CAGR, AS OBESITY BECOMES ONE OF HEALTHCARE'S MOST CAPITAL-INTENSIVE CATEGORIES MANAGEMENT BELIEVES CCX0722 REPRESENTS ONE OF COSMOS HEALTH'S MOST STRATEGICALLY SIGNIFICANT PROPRIETARY ASSETS, WITH MULTIPLE POTENTIAL PATHS TO VALUE CREATION  INCLUDING LICENSING, CO-DEVELOPMENT, AND STRATEGIC PARTNERSHIPS CHICAGO, JUNE 25, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS WHOLLY OWNED SUBSIDIARY, CANA LABORATORIES S.A. (CANA), HAS ADVANCED INTERNATIONAL PATENT APPLICATION WO2025108566A1 INTO THE EUROPEAN REGIONAL PHASE AND THE NATIONAL PHASES IN THE UNITED STATES, AUSTRALIA, AND CANADA.

COSMOS HEALTH ADVANCES INTERNATIONAL PATENT APPLICATION FOR ITS PROPRIETARY HYDROGEL WEIGHT MANAGEMENT PLATFORM ACROSS THE U.S., EUROPE, AUSTRALIA, AND CANADA

CHICAGO, JUNE 24, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY PROVIDED AN UPDATE ON THE GROWING MOMENTUM OF C-SEPT PRO, A PROPRIETARY ANTISEPTIC SOLUTION FROM ITS HIGH-MARGIN INFECTION-CONTROL PORTFOLIO, ACROSS LEADING PUBLIC AND PRIVATE HOSPITAL GROUPS IN GREECE. C-SEPT PRO HAS GENERATED AVERAGE MONTHLY SALES EXCEEDING $93,000 OVER THE PAST SIX MONTHS, ACCELERATING TO MORE THAN $108,000 PER MONTH OVER THE PAST THREE MONTHS.

COSMOS HEALTH'S C-SEPT PRO GAINS STRONG TRACTION ACROSS LEADING GREEK PUBLIC AND PRIVATE HOSPITAL GROUPS, WITH ANNUALIZED SALES POISED TO EXCEED $1.3 MILLION AT APPROXIMATELY 72% GROSS MARGIN

CHICAGO, JUNE 23, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT IT HAS SIGNED AN AGREEMENT TO DEPLOY AN ARTIFICIAL INTELLIGENCE (AI)-POWERED CALL CENTER TO SUPPORT CUSTOMER COMMUNICATIONS, INCLUDING ORDER INTAKE AND ROUTINE SUPPORT FUNCTIONS, MARKING THE LATEST STEP IN THE COMPANY'S ONGOING INTEGRATION OF AI ACROSS ITS OPERATIONS.

COSMOS HEALTH SIGNS AGREEMENT TO DEPLOY ARTIFICIAL INTELLIGENCE (AI)-POWERED CALL CENTER TO OPTIMIZE ORDER INTAKE, CUSTOMER COMMUNICATIONS, AND OPERATING EFFICIENCY

CHICAGO, JUNE 22, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY PROVIDED A CONSOLIDATED SUMMARY OF THE CONTRACT MANUFACTURING ORDERBOOK SECURED THROUGH ITS WHOLLY OWNED SUBSIDIARY, CANA LABORATORIES S.A. (CANA).

COSMOS HEALTH BUILDS CONTRACT MANUFACTURING ORDERBOOK TO OVER 25 MILLION UNITS; DIVISION POSITIONED TO GENERATE OVER $10 MILLION IN RECURRING ANNUAL PROFIT

CHICAGO, JUNE 18, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS WHOLLY OWNED SUBSIDIARY, COSMOFARM S.A. (COSMOFARM), DELIVERED RECORD REVENUE OF OVER $15 MILLION IN THE SECOND QUARTER OF 2026, REPRESENTING AN ANNUALIZED RUN-RATE OF OVER $60 MILLION.

COSMOFARM DELIVERS RECORD Q2 2026 REVENUE OF OVER $15M, REPRESENTING $60+ MILLION ANNUALIZED RUN-RATE; ADDS OVER 80 PHARMACIES AND EXPANDS AI AUTOMATION AND FACILITY CAPACITY

CHICAGO, JUNE 17, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED ITS ENTRY INTO THE GLOBAL BEAUTY AND PERSONAL CARE MARKET. SALES OF A NEW SKINCARE BRAND  A PREMIUM, KOREAN-DEVELOPED COLLAGEN-BASED SKINCARE LINE  HAVE ALREADY COMMENCED IN THE UNITED STATES AND HAVE BEEN LIVE FOR OVER A MONTH.

COSMOS HEALTH ENTERS THE $163 BILLION GLOBAL SKINCARE MARKET; SALES ALREADY UNDERWAY IN THE UNITED STATES

CHICAGO, JUNE 17, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT, THROUGH ITS WHOLLY OWNED SUBSIDIARY CANA LABORATORIES S.A. ("CANA"), IT HAS ENTERED INTO A FIVE-YEAR CONTRACT MANUFACTURING AGREEMENT WITH PHARMEX S.A.

COSMOS HEALTH SIGNS 2.86 MILLION-UNIT CONTRACT MANUFACTURING AGREEMENT WITH PHARMEX S.A. ACROSS THREE DERMATOLOGICAL PRODUCTS

CHICAGO, JUNE 15, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY PROVIDED AN UPDATE ON ITS UNITED STATES MARKET ENTRY THROUGH THE "18 SERIES," A SCIENCE-DRIVEN NUTRACEUTICAL PLATFORM BUILT ON PROPRIETARY INGREDIENTS, PUBLISHED CLINICAL RESEARCH, AND EXACT CLINICAL DOSING, AND DISCLOSED PROJECTED ANNUALIZED REVENUE AND IMPLIED GROSS PROFIT FOR FOUR OF ITS LAUNCHED PRODUCTS. SINCE LAUNCHING THE 18 SERIES IN THE U.S., COSMOS HEALTH HAS INTRODUCED FIVE PRODUCTS: NOOR18, LIV18, CUR18, FORT18, AND OLIV18  FOUR OF WHICH CURRENTLY HAVE DISCLOSED PROJECTIONS.

COSMOS HEALTH PROVIDES UPDATE ON UNITED STATES PORTFOLIO; FOUR 18 SERIES PRODUCTS INTRODUCED WITH PROJECTED ANNUALIZED REVENUE OVER $22.7M AND APPROXIMATELY $17.0M GROSS PROFIT

CHICAGO, JUNE 12, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS WHOLLY-OWNED SUBSIDIARY, CANA LABORATORIES ("CANA"), HAS RECEIVED NEW CONTRACT MANUFACTURING ORDERS FROM NASSINGTON AND VERISFIELD FOR A COMBINED 253,657 UNITS ACROSS A RANGE OF MEDICINES AND OTHER PHARMACEUTICAL PRODUCTS. UNDER THE ORDERS, CANA WILL MANUFACTURE GRITSE ORAL SOLUTION 0.4 MG/ML (BOTTLE X 150 ML); GRITSE FORTE ORAL SOLUTION 2 MG/ML (BOTTLE X 50 ML); GRITSE FORTE ORAL SOLUTION 4 MG/ML (BOTTLE X 50 ML); FUNGOFORT CUTANEOUS SPRAY, SOLUTION (30 ML); PACO-4 TABLETS (250+250+65+35 MG); DEXAMETHASONE 2 MG/5 ML, IN 50 ML AND 150 ML BOTTLE AND ORAL SOLUTION PRESENTATIONS; AND FOPROCT RECTAL CREAM (1 + 1.5%).

COSMOS HEALTH RECEIVES NEW CONTRACT MANUFACTURING ORDERS TOTALING 253,657 UNITS ACROSS A RANGE OF MEDICINES

STRONG SALES MOMENTUM: ACROSS THE UK AND GREECE, THE BRANDS' FIRST TWO MARKETS. OVER $1.5 MILLION IN SALES: C-SCRUB AND C-SEPT HAVE GENERATED OVER $1.5 MILLION IN COMBINED ANNUALIZED SALES ACROSS THE UNITED KINGDOM AND GREECE.

COSMOS HEALTH REPORTS ANNUALIZED SALES EXCEEDING $1.5M FOR ITS C-SCRUB AND C-SEPT ANTISEPTIC BRANDS IN THE UK AND GREECE; PLANS EU EXPANSION TARGETING $7.4M IN REVENUE AND $5.3M IN GROSS PROFIT

DOC PHARMA FINANCIAL PROFILE: APPROXIMATELY $24 MILLION ASSET BASE, APPROXIMATELY $6.7 MILLION IN AVERAGE ANNUAL REVENUE AND APPROXIMATELY $3.2 MILLION IN AVERAGE ANNUAL GROSS PROFIT. IMMEDIATELY ACCRETIVE: EXPECTED TO SUPPORT MARGIN EXPANSION, PROFITABILITY, AND CASH FLOW.

COSMOS HEALTH SIGNS LOI TO ACQUIRE DOC PHARMA S.A., A EUROPEAN GMP PHARMACEUTICAL MANUFACTURER, A TRANSFORMATIVE STEP EXPECTED TO BOOST ASSETS, PROFITABILITY, PRODUCTION CAPACITY, AND PRODUCT PORTFOLIO

CHICAGO, JUNE 10, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS WHOLLY-OWNED SUBSIDIARY, CANA LABORATORIES ("CANA"), HAS SECURED A THREE-YEAR CONTRACT MANUFACTURING AGREEMENT WITH VERISFIELD S.A. (VERISFIELD), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND MARKETING OF GENERIC AND DIFFERENTIATED PHARMACEUTICAL PRODUCTS ACROSS MULTIPLE THERAPEUTIC CATEGORIES.

COSMOS HEALTH SIGNS 3-YEAR CONTRACT MANUFACTURING AGREEMENT WITH VERISFIELD FOR 3.9 MILLION UNITS OF VASCLOR GEST PROGESTERONE PESSARIES

KEY HIGHLIGHTS RECORD REVENUE, CONTINUED MOMENTUM: ALL-TIME HIGH $65.3M IN FY2025; STRONGEST-EVER Q1 2026, CARRYING INTO Q2. RECORD OPERATIONAL MOMENTUM: COSMOFARM WHOLESALE DISTRIBUTION AND GMP-CERTIFIED CANA CONTRACT MANUFACTURING BOTH DELIVERING RECORD VOLUMES.

COSMOS HEALTH CEO ISSUES LETTER TO SHAREHOLDERS: BUILDING AN INNOVATIVE AI-DRIVEN GLOBAL HEALTHCARE PLATFORM  RECORD GROWTH WITH U.S. EXPANSION UNDERWAY

CHICAGO, JUNE 09, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS WHOLLY-OWNED SUBSIDIARY, CANA LABORATORIES ("CANA"), HAS INAUGURATED A NEW, STATE-OF-THE-ART CAPSULE PRODUCTION LINE AND SECURED AN ADDITIONAL CONTRACT MANUFACTURING AGREEMENT WITH PROVIDENT PHARMACEUTICALS ("PROVIDENT"), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE COMMERCIALIZATION AND MARKETING OF NICHE AND LEGACY PHARMACEUTICAL PRODUCTS AND MEDICAL DEVICES IN SPECIFIC THERAPEUTIC AREAS. UNDER THE NEW FIVE-YEAR AGREEMENT, CANA WILL MANUFACTURE 385,000 UNITS OF CERTORUN (SERTRALINE HYDROCHLORIDE) OVER THE FIVE-YEAR PERIOD, AT AN ANNUAL PRODUCTION VOLUME OF 77,000 UNITS.

COSMOS HEALTH INAUGURATES STATE-OF-THE-ART CAPSULE PRODUCTION LINE WITH NEW 5-YEAR CONTRACT MANUFACTURING AGREEMENT WITH PROVIDENT PHARMACEUTICALS FOR 385,000 UNITS OF CERTORUN

KEY HIGHLIGHTS CANA LABORATORIES, COSMOS HEALTH'S WHOLLY OWNED SUBSIDIARY, ACQUIRES INTERNATIONAL PATENT APPLICATION WO2025108566A1 FROM CLOUDPHARM P.C. PATENT PROTECTION BEING PURSUED AT NATIONAL AND REGIONAL LEVELS ACROSS KEY INTERNATIONAL MARKETS TECHNOLOGY SUPPORTS NEXT-GENERATION PHARMACEUTICAL, NUTRACEUTICAL, OTC, AND SPECIALIZED HEALTHCARE PRODUCT DEVELOPMENT EXPANDS NANOTECHNOLOGY INVESTMENT INITIATIVES, LEVERAGING CANA LABORATORIES' EUROPEAN GMP-CERTIFIED MANUFACTURING CAPABILITIES ALIGNED WITH THE COMPANY'S BROADER STRATEGY OF EXPANDING ITS IP PORTFOLIO, STRENGTHENING VERTICAL INTEGRATION, AND DRIVING LONG-TERM SHAREHOLDER VALUE CHICAGO, JUNE 08, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS WHOLLY OWNED SUBSIDIARY, CANA LABORATORIES S.A.

COSMOS HEALTH COMPLETES ACQUISITION OF STRATEGIC INTELLECTUAL PROPERTY AND EXPANDS NANOTECHNOLOGY INVESTMENT INITIATIVES

OLIV18 EXPANDS THE 18 SERIES WITH A USDA AND EU ORGANIC CERTIFIED, 100% SOLVENT-FREE, WHOLE OLIVE POLYPHENOL FORMULATION FROM THE MOROCCAN SAHARAN DESERT HYDROXYTYROSOL  THE KEY ACTIVE IN OLIV18  IS THE HIGHEST ORAC POLYPHENOL A SINGLE 250 MG DAILY DOSE MEETS EFSA'S 5 MG/DAY HYDROXYTYROSOL MINIMUM DOSE FOR PROTECTION AGAINST LDL OXIDATION A SINGLE DAILY DOSE EQUIVALENT TO APPROXIMATELY 11 TEASPOONS OF GOOD QUALITY EXTRA VIRGIN OLIVE OIL  COMPARED TO AN AVERAGE OF HALF A TEASPOON PER DAY IN THE U.S. TARGETING THE MULTIBILLION CARDIOVASCULAR HEALTH AND ANTIOXIDANT MARKETS, INITIALLY IN THE UNITED STATES AND GLOBALLY THEREAFTER  WITHIN A COMBINED GLOBAL MARKET LANDSCAPE PROJECTED TO EXCEED $33 BILLION BY 2035 CHICAGO, JUNE 05, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. (COSMOS HEALTH OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THE U.S. LAUNCH OF OLIV18, FURTHER EXPANDING ITS SCIENCE-DRIVEN 18 SERIES NUTRACEUTICAL PLATFORM INTO CARDIOVASCULAR AND ANTIOXIDANT CATEGORIES. SCIENTIFIC BACKGROUND OLIV18 IS FORMULATED WITH A WHOLE OLIVE POLYPHENOL EXTRACT DERIVED FROM THE FRUIT AND LEAF OF OLIVE TREES CULTIVATED IN THE MOROCCAN STRETCH OF THE SAHARAN DESERT.

COSMOS HEALTH CONTINUES U.S. EXPANSION WITH LAUNCH OF OLIV18, TARGETING CARDIOVASCULAR AND ANTIOXIDANT CATEGORIES

CHICAGO, JUNE 04, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED THAT ITS PROPRIETARY BRAND, SKY PREMIUM LIFE, IS NOW AVAILABLE FOR SHIPMENT ACROSS ALL 27 EUROPEAN UNION MEMBER STATES THROUGH SKROUTZ, SIGNIFICANTLY EXPANDING THE BRAND'S INTERNATIONAL REACH. A TOTAL OF 96 SKY PREMIUM LIFE PRODUCTS ARE NOW ACCESSIBLE TO CONSUMERS ACROSS ALL 27 EUROPEAN UNION MEMBER STATES THROUGH SKROUTZ, WITH SHIPMENTS REACHING KEY MARKETS ACROSS WESTERN EUROPE, NORTHERN EUROPE, AND CENTRAL AND EASTERN EUROPE.

COSMOS HEALTH ACHIEVES PAN-EUROPEAN DISTRIBUTION FOR SKY PREMIUM LIFE ACROSS ALL 27 EU MEMBER STATES THROUGH LEADING E-COMMERCE PLATFORM SKROUTZ

COMPANY IDENTIFIES REAL ESTATE, DIGITAL ASSETS, AND MARKETABLE SECURITIES, AMONG OTHERS, AS POTENTIAL SOURCES OF LIQUIDITY  WITH A COMBINED VALUE OF APPROXIMATELY $20 MILLION PROCEEDS COULD FUND A MEANINGFUL ACQUISITION OR ELIMINATE DEBT ENTIRELY COMPANY REMAINS FULLY COMMITTED TO ITS CORE HEALTHCARE OPERATIONS CHICAGO, JUNE 04, 2026 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, TODAY ANNOUNCED IT IS EXPLORING THE MONETIZATION OF NON-CORE ASSETS, HAVING IDENTIFIED APPROXIMATELY $20 MILLION IN ASSETS THAT CAN BE CONVERTED TO LIQUIDITY WITHOUT IMPACTING THE COMPANY'S OPERATIONAL CAPABILITIES. THE COMPANY IS FULLY COMMITTED TO ITS CORE HEALTHCARE OPERATIONS AND VIEWS THESE ASSETS AS NON-CORE IN THE SENSE THAT THEY CAN BE MONETIZED TO STRENGTHEN THE BALANCE SHEET, FUND STRATEGIC INITIATIVES, AND CLOSE THE GAP BETWEEN INTRINSIC VALUE AND CURRENT MARKET VALUATION.

Cosmos Health Inc.

COSM

Price

Financial Reports

No items found.

Press Releases

Cosmos Health Inc.

COSM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

COSM